Vasomune Therapeutics to Present on Pegevongitide Therapeutic Capability at the 2026 NATO NSPA CBRN

Dr. Brian Jahns will present a therapeutics capability update of Pegevongitide (AV-001), Vasomune’s dual-use drug candidate targeting vascular leak, an underlying pathology across casualty care TORONTO — Vasomune Therapeutics, Inc. (“Vasomune”), a clinical-stage biopharmaceutical company developing therapies that target vascular leak, today announced that the company has been invited to present at the 2026 NATO […]